PLYMOUTH
MEETING, Pa., Oct. 25,
2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and prevent infectious diseases, cancer,
and diseases associated with HPV, announced today that third
quarter 2022 financial results will be released after the market
close on November 8, 2022. Following
the release, INOVIO will host a live conference call and webcast at
4:30 p.m. ET to discuss financial
results and provide a general business update.
A live and archived version of the audio presentation will be
available online at
http://ir.inovio.com/events-and-presentations/default.aspx. This is
a listen-only event but will include a live Q&A with
analysts.
About INOVIO
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help treat and protect people from
infectious diseases, cancer, and diseases associated with HPV. Our
DNA medicines in development are delivered using our
investigational proprietary smart device to produce immune
responses against targeted pathogens and cancers. For more
information, visit www.inovio.com.
Contacts
Investors & Media:
Gene
Kim, (267) 589-9471, gene.kim@inovio.com
Thomas Hong, (267) 440-4298,
thomas.hong@inovio.com
View original
content:https://www.prnewswire.com/news-releases/inovio-to-report-third-quarter-2022-financial-results-on-november-8-2022-301658101.html
SOURCE INOVIO Pharmaceuticals, Inc.